Please enable Javascript
Christopher Benton, MD
Articles by Christopher Benton, MD
ESAs-Only MDS Management: Does the Real-World Experience Differ from Clinical Trials?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
View More
Can EMR Alerts Help Optimize Luspatercept Dosing in MDS?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
View More
Does Luspatercept Reduce Health Care Systems’ Resource Utilization Burden in MDS?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
View More
Discussing the Impact of Luspatercept on Cell Lineages in MDS
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 29, 2024
The expert panel discussion led by Jamile Shammo, MD, also noted differences in cell line suppression by mutational profile.
View More
What Major Themes Define Recent Lower-Risk MDS Prognostication, Treatment?
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 23, 2024
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
View More
What to Know About Optimal Luspatercept Use in Lower-Risk MDS
Jamile Shammo, MD
Myelodysplastic Syndromes
|
October 23, 2024
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
View More